Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The UNIVERSITY OF CAPE TOWN currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 5 distinct art units. CUTLIFF, YATE KAI RENE is the busiest examiner for the university, overseeing 1 busiest examiner pending action.
The distribution of 6 pending office actions across 6 distinct examiners indicates a decentralized prosecution strategy. With 5 distinct art units involved, the university's technical focus is spread across multiple examination groups within the Biotechnology & Pharmaceuticals sector. This 6 to 6 ratio of actions to examiners means that each examiner manages exactly one matter for the university.
For a practitioner, managing 6 pending office actions requires coordinating with 6 distinct examiners. The involvement of 5 distinct art units suggests that the university's technology has a broad technical footprint. CUTLIFF, YATE KAI RENE handles 1 busiest examiner pending action, which matches the workload of the other distinct examiners. This level of dispersion across 5 distinct art units requires a broad understanding of different examiner tendencies within the biotechnology field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUTLIFF, YATE KAI RENE | 1 | 79.8% | +24.3% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
| DEVI, SARVAMANGALA | 1 | 65.3% | +55.3% |
| DIPERT, FORREST BLAKE | 1 | 50.0% | +64.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253755 | USE OF MICROVIRIN IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS MANNOSE-CAPPED LIPOARABINOMANNAN | DEVI, SARVAMANGALA | 14d |
| 18685337 | Selective Aerobic Oxidation of Methane | CUTLIFF, YATE KAI RENE | — |
| 18553024 | TARGETS OVEREXPRESSED ON THE SURFACE OF CANCER CELLS | MYERS, CARLA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294596 | SMALL MOLECULE INHIBITORS FOR ANTI-CANCER COMBINATION THERAPY | COLEMAN, BRENDA LIBBY | 6d |
| 18253755 | USE OF MICROVIRIN IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS MANNOSE-CAPPED LIPOARABINOMANNAN | DEVI, SARVAMANGALA | 14d |
| 18685337 | Selective Aerobic Oxidation of Methane | CUTLIFF, YATE KAI RENE | — |
| 18568456 | TOBAMOVIRUS PSEUDOVIRIONS FOR STABILISING SINGLE STRANDED RNA | KELLY, ROBERT M | — |
| 18553024 | TARGETS OVEREXPRESSED ON THE SURFACE OF CANCER CELLS | MYERS, CARLA J | — |
| 17634482 | System and Method for Infusion of Drugs | DIPERT, FORREST BLAKE | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1638 | 1 |
| 1682 | 1 |
| 1645 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685337 | Selective Aerobic Oxidation of Methane | CUTLIFF, YATE KAI RENE | — | §103§112 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18294596 | SMALL MOLECULE INHIBITORS FOR ANTI-CANCER COMBINATION THERAPY | COLEMAN, BRENDA LIBBY | 1624 | §112 | Final Rejection | 6d | Pending | Feb 02, 2024 |
| 18568456 | TOBAMOVIRUS PSEUDOVIRIONS FOR STABILISING SINGLE STRANDED RNA | KELLY, ROBERT M | 1638 | §103 | Final Rejection | — | Pending | Dec 08, 2023 |
| 18553024 | TARGETS OVEREXPRESSED ON THE SURFACE OF CANCER CELLS | MYERS, CARLA J | 1682 | §101§103§112 | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18253755 | USE OF MICROVIRIN IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS MANNOSE-CAPPED LIPOARABINOMANNAN | DEVI, SARVAMANGALA | 1645 | §103§112 | Non-Final OA | 14d | Pending | May 19, 2023 |
| 17634482 | System and Method for Infusion of Drugs | DIPERT, FORREST BLAKE | 3783 | §103 | Non-Final OA | — | Pending | Feb 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial